Ambryice M Riggs

Publications (3)68.82 Total impact

• Article: Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.

  Dan H Barouch, Kara L O'Brien, Nathaniel L Simmons, Sharon L King, Peter Abbink, Lori F Maxfield, Ying-Hua Sun, Annalena La Porte, Ambryice M Riggs, Diana M Lynch, Sarah L Clark, Katherine Backus, James R Perry, Michael S Seaman, Angela Carville, Keith G Mansfield, James J Szinger, Will Fischer, Mark Muldoon, Bette Korber
  [show abstract] [hide abstract]
  ABSTRACT: The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development. Antigens derived from natural HIV-1 sequences have elicited only a limited breadth of cellular immune responses in nonhuman primate studies and clinical trials to date. Polyvalent 'mosaic' antigens, in contrast, are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity. Here we show that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses as compared with consensus or natural sequence HIV-1 antigens in rhesus monkeys. Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1.
  Nature medicine 02/2010; 16(3):319-23. · 27.14 Impact Factor
• Article: Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys.

  Dan H Barouch, Jinyan Liu, Diana M Lynch, Kara L O'Brien, Annalena La Porte, Nathaniel L Simmons, Ambryice M Riggs, Sarah Clark, Peter Abbink, David C Montefiori, Gary Landucci, Donald N Forthal, Steven G Self, Angela Carville, Keith Mansfield, Jaap Goudsmit
  [show abstract] [hide abstract]
  ABSTRACT: Rare serotype and chimeric recombinant adenovirus (rAd) vectors that evade anti-Ad5 immunity are currently being evaluated as potential vaccine vectors for human immunodeficiency virus type 1 and other pathogens. We have recently reported that a heterologous rAd prime-boost regimen expressing simian immunodeficiency virus (SIV) Gag afforded durable partial immune control of an SIV challenge in rhesus monkeys. However, single-shot immunization may ultimately be preferable for global vaccine delivery. We therefore evaluated the immunogenicity and protective efficacy of a single immunization of chimeric rAd5 hexon hypervariable region 48 (rAd5HVR48) vectors expressing SIV Gag, Pol, Nef, and Env against a homologous SIV challenge in rhesus monkeys. Inclusion of Env resulted in improved control of peak and set point SIV RNA levels following challenge. In contrast, DNA vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system.
  Journal of Virology 07/2009; 83(18):9584-90. · 5.40 Impact Factor
• Article: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

  Jinyan Liu, Kara L O'Brien, Diana M Lynch, Nathaniel L Simmons, Annalena La Porte, Ambryice M Riggs, Peter Abbink, Rory T Coffey, Lauren E Grandpre, Michael S Seaman, Gary Landucci, Donald N Forthal, David C Montefiori, Angela Carville, Keith G Mansfield, Menzo J Havenga, Maria G Pau, Jaap Goudsmit, Dan H Barouch
  [show abstract] [hide abstract]
  ABSTRACT: A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans. Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref. 3). Here we show that an improved T-cell-based vaccine regimen using two serologically distinct adenovirus vectors afforded substantially improved protective efficacy in this challenge model. In particular, a heterologous rAd26 prime/rAd5 boost vaccine regimen expressing SIV Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen. After SIV(MAC251) challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals. These data demonstrate that durable partial immune control of a pathogenic SIV challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen. These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1.
  Nature 12/2008; 457(7225):87-91. · 36.28 Impact Factor